Geneva, Switzerland and Boston, MA – Tuesday 14 April, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss…
Category: Press release
The press releases from ObsEva
ObsEva SA Announces New Interim Chief Financial Officer
Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
ObsEva SA: New Date Announcement for AGM
Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
ObsEva Provides Update Related to COVID-19 Pandemic
Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20,…
ObsEva SA Link to Annual Report 2019
Geneva, Switzerland and Boston, MA – March 5, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
ObsEva Announces Year End 2019 Financial Results and Business Update
Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3…
ObsEva SA to Hold Year End 2019 Financial Results and Business Update Conference Call on March 5, 2020
Geneva, Switzerland and Boston, MA – February 27, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…
ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020
Geneva, Switzerland and Boston, MA – February 18, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing…
ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned…
ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People’s Republic of China
Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a…